# Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome

Study · id `cardio:ct-nct07497776` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07497776](<https://clinicaltrials.gov/study/NCT07497776>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07497776

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT07497776. Non-randomized; no masking; primary purpose supportive care. Start 2024-01-27 (actual); primary completion 2025-08-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose supportive care
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT07497776, source copy `cardio:ctgov-nct07497776-2026-03-27`, retrieved 2026-10-31)
- Started: 2024-01-27 (actual) (ClinicalTrials.gov record NCT07497776, source copy `cardio:ctgov-nct07497776-2026-03-27`, retrieved 2026-10-31)
- Primary completion: 2025-08-30 (actual) (ClinicalTrials.gov record NCT07497776, source copy `cardio:ctgov-nct07497776-2026-03-27`, retrieved 2026-10-31)
- Completion: 2025-10-31 (actual) (ClinicalTrials.gov record NCT07497776, source copy `cardio:ctgov-nct07497776-2026-03-27`, retrieved 2026-10-31)
- Countries: Bangladesh (ClinicalTrials.gov record NCT07497776, source copy `cardio:ctgov-nct07497776-2026-03-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07497776-2026-03-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome
- Condition: Dyslipidaemia
- Intervention (Drug): Atorvastatin
- Lead sponsor: National Institute of Kidney Disease and Urology (NIKDU)
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)

## Provenance

Content hash: ed9ca9844622d8c8b929402ae07ae5d5f795792649fd973aecb2209c69f26af5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
